85 related articles for article (PubMed ID: 25738923)
1. Differential proteomic profiling of primary and recurrent chordomas.
Chen S; Xu W; Jiao J; Jiang D; Liu J; Chen T; Wan Z; Xu L; Zhou Z; Xiao J
Oncol Rep; 2015 May; 33(5):2207-18. PubMed ID: 25738923
[TBL] [Abstract][Full Text] [Related]
2. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.
Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A
Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide DNA methylation profiling of recurrent and non-recurrent chordomas.
Alholle A; Brini AT; Bauer J; Gharanei S; Niada S; Slater A; Gentle D; Maher ER; Jeys L; Grimer R; Sumathi VP; Latif F
Epigenetics; 2015; 10(3):213-20. PubMed ID: 25621392
[TBL] [Abstract][Full Text] [Related]
4. Characterization of cancer stem-like cells in chordoma.
Aydemir E; Bayrak OF; Sahin F; Atalay B; Kose GT; Ozen M; Sevli S; Dalan AB; Yalvac ME; Dogruluk T; Türe U
J Neurosurg; 2012 Apr; 116(4):810-20. PubMed ID: 22283189
[TBL] [Abstract][Full Text] [Related]
5. Molecular features and vulnerabilities of recurrent chordomas.
Seeling C; Lechel A; Svinarenko M; Möller P; Barth TFE; Mellert K
J Exp Clin Cancer Res; 2021 Jul; 40(1):244. PubMed ID: 34330313
[TBL] [Abstract][Full Text] [Related]
6. Differential proteomic profiling of chordomas and analysis of prognostic factors.
Zhou H; Chen CB; Lan J; Liu C; Liu XG; Jiang L; Wei F; Ma QJ; Dang GT; Liu ZJ
J Surg Oncol; 2010 Dec; 102(7):720-7. PubMed ID: 20721957
[TBL] [Abstract][Full Text] [Related]
7. Whole-transcriptome analysis of chordoma of the skull base.
Bell D; Raza SM; Bell AH; Fuller GN; DeMonte F
Virchows Arch; 2016 Oct; 469(4):439-49. PubMed ID: 27401718
[TBL] [Abstract][Full Text] [Related]
8. Unravelling the role of immune cells and FN1 in the recurrence and therapeutic process of skull base chordoma.
Huo X; Ma S; Wang C; Song L; Yao B; Zhu S; Li P; Wang L; Wu Z; Wang K
Clin Transl Med; 2023 Oct; 13(10):e1429. PubMed ID: 37784253
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome comparison identifies potential biomarkers of spine and skull base chordomas.
Bell AH; DeMonte F; Raza SM; Rhines LD; Tatsui CE; Prieto VG; Fuller GN; Bell D
Virchows Arch; 2018 Mar; 472(3):489-497. PubMed ID: 28844110
[TBL] [Abstract][Full Text] [Related]
10. Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.
Kitamura Y; Sasaki H; Kimura T; Miwa T; Takahashi S; Kawase T; Yoshida K
J Neuropathol Exp Neurol; 2013 Sep; 72(9):816-23. PubMed ID: 23965741
[TBL] [Abstract][Full Text] [Related]
11. PARP1 is a novel independent prognostic factor for the poor prognosis of chordoma.
Li Z; Lv T; Liu Y; Huang X; Qiu Z; Li J
Cancer Biomark; 2016 Mar; 16(4):633-9. PubMed ID: 27002766
[TBL] [Abstract][Full Text] [Related]
12. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
13. Long-term control of clival chordoma with initial aggressive surgical resection and gamma knife radiosurgery for recurrence.
Ito E; Saito K; Okada T; Nagatani T; Nagasaka T
Acta Neurochir (Wien); 2010 Jan; 152(1):57-67; discussion 67. PubMed ID: 19826755
[TBL] [Abstract][Full Text] [Related]
14. New candidate chromosomal regions for chordoma development.
Bayrakli F; Guney I; Kilic T; Ozek M; Pamir MN
Surg Neurol; 2007 Oct; 68(4):425-30; discussion 430. PubMed ID: 17714767
[TBL] [Abstract][Full Text] [Related]
15. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
16. Sacral chordomas: Impact of high-dose proton/photon-beam radiation therapy combined with or without surgery for primary versus recurrent tumor.
Park L; Delaney TF; Liebsch NJ; Hornicek FJ; Goldberg S; Mankin H; Rosenberg AE; Rosenthal DI; Suit HD
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1514-21. PubMed ID: 16757128
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of chordoma.
Scheil-Bertram S; Kappler R; von Baer A; Hartwig E; Sarkar M; Serra M; Brüderlein S; Westhoff B; Melzner I; Bassaly B; Herms J; Hugo HH; Schulte M; Möller P
Int J Oncol; 2014 Apr; 44(4):1041-55. PubMed ID: 24452533
[TBL] [Abstract][Full Text] [Related]
18. Chordoma: the nonsarcoma primary bone tumor.
Chugh R; Tawbi H; Lucas DR; Biermann JS; Schuetze SM; Baker LH
Oncologist; 2007 Nov; 12(11):1344-50. PubMed ID: 18055855
[TBL] [Abstract][Full Text] [Related]
19. Shedding light on emerging therapeutic targets for chordoma.
Martinez Moreno M; Wang E; Schroeder C; Sullivan P; Gokaslan Z
Expert Opin Ther Targets; 2023; 27(8):705-713. PubMed ID: 37647357
[TBL] [Abstract][Full Text] [Related]
20. ALCAM (CD166) expression as novel prognostic biomarker for pancreatic neuroendocrine tumor patients.
Tachezy M; Zander H; Marx AH; Gebauer F; Rawnaq T; Kaifi JT; Sauter G; Izbicki JR; Bockhorn M
J Surg Res; 2011 Oct; 170(2):226-32. PubMed ID: 21816425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
